Septicemia,Access,Cardiovascular Disease,and Death in Dialysis Patients

2003 annual report: ESRD clinical performance measures project. Am J Kidney Dis 2004; 44(2 Suppl 2): A5–6, S1–92.

Sarnak M.J. , Jaber B.L. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758–64.

Foley R.N. , Guo H. , Snyder J.J. , Gilbertson D.T. , Collins A.J. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 2004; 15: 1038–45.

Marr K.A. , Sexton D.J. , Conlon P.J. , Corey G.R. , Schwab S.J. , Kirkland K.B. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127: 275–80.

Hoen B. , Paul-Dauphin A. , Hestin D. , Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869–76.

Ishani A. , Collins A.J. , Herzog C.A. , Foley R.N. Septicemia, access and cardiovascular disease in dialysis patients: The USRDS Wave 2 study. Kidney Int 2005; 68: 311–18.

Abraham E. , Matthay M.A. , Dinarello C.A. , Vincent J.L. , Cohen J. , Opal S.M. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation. Crit Care Med 2000; 28: 232–5.

Cohen J. , Guyatt G. , Bernard G.R. , Calandra T. , Cook D. , Elbourne D. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001; 29: 880–6.

Zahorec R. Definition for septic syndrome should be reevaluated. Intensive Care Med 2000; 26: 1870.

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–26.

Ridker P.M. , Cushman M. , Stampfer M.J. , Tracy R.P. , Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.

Ridker P.M. , Hennekens C.H. , Buring J.E. , Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43.

Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–95.

Saikku P. , Leinonen M. , Mattila K. , Ekman M.R. , Nieminen M.S. , Makela P.H. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2(8618): 983–6.

O'Connor C.M. , Dunne M.W. , Pfeffer M.A. , Muhlestein J.B. , Yao L. , Gupta S. Azithromycin for the secondary prevention of coronary heart disease events: The WIZARD study: A randomized controlled trial. JAMA 2003; 290: 1459–66.

Cercek B. , Shah P.K. , Noc M. , Zahger D. , Zeymer U. , Matetzky S. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: A randomised controlled trial. Lancet 2003; 361(9360): 809–13.

Grayston J.T. , Kronmal R.A. , Jackson L.A. , Parisi A.F. , Muhlestein J.B. , Cohen J.D. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637–45.

Cannon C.P. , Braunwald E. , McCabe C.H. , Grayston J.T. , Muhlestein B. , Giugliano R.P. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646–54.

Soderberg-Naucler C. , Emery V.C. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001; 71(11 Suppl): SS24–30.

Hotchkiss R.S. , Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138–50.

Stenvinkel P. , Heimburger O. , Paultre F. , Diczfalusy U. , Wang T. , Berglund L. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–911.

Kaysen G.A. , Eiserich J.P. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial 2003; 16: 438–46.

Levin A. , Mason A.J. , Jindal K.K. , Fong I.W. , Goldstein M.B. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int 1991; 40: 934–8.

Boelaert J.R. , Van Landuyt H.W. , Godard C.A. , Daneels R.F. , Schurgers M.L. , Matthys E.G. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235–9.

Sesso R. , Barbosa D. , Leme I.L. , Sader H. , Canziani M.E. , Manfredi S. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J Am Soc Nephrol 1998; 9: 1085–92.

Johnson D.W. , MacGinley R. , Kay T.D. , Hawley C.M. , Campbell S.B. , Isbel N.M. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17: 1802–7.

Lok C.E. , Stanley K.E. , Hux J.E. , Richardson R. , Tobe S.W. , Conly J. Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol 2003; 14: 169–79.

Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 2003; 36: 1539–44.

Shah C.B. , Mittelman M.W. , Costerton J.W. , Parenteau S. , Pelak M. , Arsenault R. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46: 1674–9.

Vercaigne L.M. , Zelenitsky S.A. , Findlay I. , Bernstein K. , Penner S.B. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother 2002; 49: 693–6.

Weijmer M.C. , Debets-Ossenkopp Y.J. , Van De Vondervoort F.J. , ter Wee P.M. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002; 17: 2189–95.

Dogra G.K. , Herson H. , Hutchison B. , Irish A.B. , Heath C.H. , Golledge C. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: A randomized controlled study. J Am Soc Nephrol 2002; 13: 2133–9.

McIntyre C.W. , Hulme L.J. , Taal M. , Fluck R.J. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004; 66: 801–5.

Yu V.L. , Goetz A. , Wagener M. , Smith P.B. , Rihs J.D. , Hanchett J. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315: 91–6.

Shinefield H. , Black S. , Fattom A. , Horwith G. , Rasgon S. , Ordonez J. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346: 491–6.

Weijmer M.C. , van den Dorpel M.A. , Van de Ven P.J. , ter Wee P.M. , van Geelen J.A. , Groeneveld J.O. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2769–77.

III. NKF-K/DOQI Clinical practice guidelines for vascular access: Update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1): S137–81.

United States Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004: 102–6. Avalilable at URL: www.usrds.org/2004/pdf/05_clinical_care_04.pdf

Sands J. , Miranda C.L. Increasing numbers of AV fistulas for hemodialysis access. Clin Nephrol 1997; 48: 114–17.

Konner K. Increasing the proportion of diabetics with AV fistulas. Semin Dial 2001; 14: 1–4.

Saxena A.K. , Panhotra B.R. , Naguib M. , Sundaram D.S. , Venkateshappa C.K. , Uzzaman W. Outcome of dialysis access-related septicemia among diabetics following optimized AV-fistula placement. Kidney Blood Press Res 2002; 25: 109–14.

Oliver M.J. , Rothwell D.M. , Fung K. , Hux J.E. , Lok C.E. Late creation of vascular access for hemodialysis and increased risk of sepsis. J Am Soc Nephrol 2004; 15: 1936–42.

Crabtree J.H. , Burchette R.J. , Siddiqi R.A. , Huen I.T. , Hadnott L.L. , Fishman A. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003; 23: 368–74.

Danielsson A. , Blohme L. , Tranaeus A. , Hylander B. A prospective randomized study of the effect of a subcutaneously “buried” peritoneal dialysis catheter technique versus standard technique on the incidence of peritonitis and exit-site infection. Perit Dial Int 2002; 22: 211–19.

Warchol S. , Roszkowska-Blaim M. , Latoszynska J. , Jarmolinski T. , Zachwieja J. Experience using presternal catheter for peritoneal dialysis in Poland: A multicenter pediatric survey. Perit Dial Int 2003; 23: 242–8.

Strippoli G.F. , Tong A. , Johnson D. , Schena F.P. , Craig J.C. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: A systematic review of randomized, controlled trials. J Am Soc Nephrol 2004; 15: 2735–46.

Daly C.D. , Campbell M.K. , MacLeod A.M. , Cody D.J. , Vale L.D. , Grant A.M. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol Dial Transplant 2001; 16: 341–7.

Piraino B. , Perlmutter J.A. , Holley J.L. , Bernardini J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit Dial Int 1993; 13(Suppl 2): S332–4.

Luzar M.A. , Coles G.A. , Faller B. , Slingeneyer A. , Dah G.D. , Briat C. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322: 505–9.

Perez-Fontan M. , Rosales M. , Rodriguez-Carmona A. , Moncalian J. , Fernandez-Rivera C. , Cao M. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992; 8: 242–5.

Annigeri R. , Conly J. , Vas S. , Dedier H. , Prakashan K.P. , Bargman J.M. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21: 554–9.

Berns J.S. , Tokars J.I. Preventing bacterial infections and antimicrobial resistance in dialysis patients. Am J Kidney Dis 2002; 40: 886–98.

Vychytil A. , Lorenz M. , Schneider B. , Horl W.H. , Haag-Weber M. New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients. J Am Soc Nephrol 1998; 9: 669–76.

Bernardini J. , Piraino B. , Holley J. , Johnston J.R. , Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27: 695–700.

Keane W.F. , Bailie G.R. , Boeschoten E. , Gokal R. , Golper T.A. , Holmes C.J. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update [Published erratum appears in Perit Dial Int 2000; 20: 828–9]. Perit Dial Int 2000; 20: 396–411.

Bernardini J. , Bender F. , Florio T. , Sloand J. , Palmmontalbano L. , Fried L. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16: 539–45.